Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials

Antenatal Stress and Infants In MAR

NCT07408453
Recruiting
Conditions Pregnancy and Medically Assisted Reprodu...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational longitudinal study is to examine the association between prenatal psychological and biological stress and neonatal health outcomes in couples who conceived through medically assisted reproduction. The study includes expectant mothers and fathers during pregnancy and at birth and focuses on pregnancies achieved through homologous fertilization and heterologous fertilization via oocyte donation. The main questions this study aims to answer are: 1. How do psychological and biological indicators of stress manifest during pregnancy in women who have undergone medically assisted reproduction? 2. Is prenatal maternal stress associated with neonatal health outcomes independently of genetic factors? 3. How does perceived stress present in expectant fathers during pregnancy? Researchers will compare couples who conceived through homologous fertilization with couples who conceived through heterologous fertilization via oocyte donation to understand whether associations between prenatal maternal stress and neonatal outcomes are independent of shared genetic background. Participants will: * Complete a remote eligibility assessment collecting information on pregnancy characteristics, parental health, and maternal psychological well-being * Complete online questionnaires at multiple time points during pregnancy and at birth assessing anxiety and depressive symptoms, perceived social support, and self-efficacy (both parents), as well as pregnancy-specific measures and prenatal bonding (mothers only) * In late pregnancy, mothers will collect saliva samples at home over two consecutive days to assess biological markers of stress (cortisol and alpha-amylase)

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Other: Diagnostic procedures — psychological and biological multimodal assessment of stress

Primary Outcomes

  • Maternal Anxiety (Assessed in the 1st trimester (11th-13th week), 2nd trimester (22nd-24th week), 3rd trimester (34th-36th week), and at birth.)
  • Maternal Depression (Assessed in the 1st trimester (11th-13th week), 2nd trimester (22nd-24th week), 3rd trimester (34th-36th week), and at birth.)
  • Maternal salivary cortisol (3rd trimester (34th-36th week of pregnancy))
  • Maternal salivary alpha amylase (3rd trimester (34th-36th week of pregnancy).)
  • Paternal Anxiety (1st trimester (11th-13th week), 2nd trimester (22nd-24th week), 3rd trimester (34th-36th week), and at birth)
  • Paternal depression (1st trimester (11th-13th week), 2nd trimester (22nd-24th week), 3rd trimester (34th-36th week), and at birth.)
  • Neonatal Outcomes (At birth)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-04
Completion: 2027-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: IRCCS Eugenio Medea
Collaborators: A.O. Ospedale Papa Giovanni XXIII
Contact Information
Study Contact:
Alessandra Frigerio, PhD
+39031877595
alessandra.frigerio@lanostrafamiglia.it
Simone Forni
+39031877111
simone.forni@lanostrafmiglia.it
Head of the Assisted Reproduction Unit, MD
+39035267111
ffusi@asst-pg23.it
Ospedale Papa Giovanni XXIII
Interventions
  • Other: Diagnostic procedures — psychological and biological multimodal assessment of stress
Study Locations (1 sites)
Ospedale Papa Giovanni XXIII, Bergamo, Bergamo 24127 Italy
Eligibility Criteria
Inclusion Criteria: * Pregnant women in the first trimester and their respective partners. * Pregnancy achieved through homologous assisted reproduction techniques. * Pregnancy achieved through heterologous assisted reproduction via oocyte donation. * Singleton pregnancy. * Pregnancy achieved through FIVET techniques. Exclusion Criteria: * Parents under 18 years of age. * Pregnancy achieved through heterologous assisted reproduction via donor sperm. * Pregnancy achieved without FIVET techniques. * Maternal hypertension during pregnancy. * Endocrine or immune system disorders during pregnancy. * Chronic use of medications during pregnancy (including anti-inflammatory drugs, antidepressants, or steroids). * Alcohol or substance abuse. * Smoking during pregnancy. * Psychiatric disorders other than anxiety or depression. * Pregnancy or perinatal complications. * Multiple pregnancy (twins or higher-order multiples). * Preterm birth (before 35 weeks of gestation). * Health problems in the newborn at birth.
Conditions Depression
Phase NA
Enrollment 256
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

This study is a randomized Type I hybrid effectiveness-implementation trial aimed at evaluating the effectiveness of Empower@Home, an internet-delivered cognitive-behavioral therapy (CBT) program supported by aging service providers, in comparison to enhanced usual care for homebound older adults with depressive symptoms. A total of 256 participants will be randomly assigned to either the treatment group (Empower@Home) or the control group (enhanced usual care) in a 1:1 allocation ratio, with randomization stratified by participating agencies. The primary aim of this study is to determine the clinical effectiveness of the Empower@Home program. It is hypothesized that participants receiving Empower@Home will show greater improvements in depressive symptoms at 12, 24, and 36 weeks after entering the study compared to those receiving enhanced usual care. Additionally, treatment moderators will be explored and a cost-effectiveness analysis will be conducted to assess the economic viability of the intervention. The second aim is to investigate the mechanisms of change facilitated by the intervention using a mixed-methods approach. Causal mediation analysis will examine whether the acquisition of CBT skills, reduction in cognitive distortions, and increased behavioral activation, as well as participant engagement and the therapeutic alliance with the coach, mediate the treatment effects. Qualitative interviews with participants will be conducted to provide deeper insights into these mechanisms and enhance the interpretation of the mediation analysis. The third aim focuses on evaluating the implementation process using the updated Consolidated Framework for Implementation Research (CFIR). This will involve a qualitative process evaluation to identify barriers and facilitators to the implementation of Empower@Home, drawing on perspectives from multiple stakeholders.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Empower@Home: An online cognitive-behavioral therapy self-care program for geriatric depression — Empower@Home is an online self-help intervention based on cognitive behavioral therapy principles designed to treat depressive symptoms in older adults. The intervention has three components: 9 interactive self-paced online sessions, printed workbook that goes along the online sessions for exercises and homework, and telephone coaching by a trained staff from a social service agency serving older adults. The online sessions contain entertainment elements in the form of a character-driven story of a homebound older adults, video-based psycho-educational content, voice-over instructions, interactive exercises, and weekly home practice assignments.
  • Other: Telephone friendly visits — Participants in the waitlist control group will receive attention control through biweekly telephone-friendly visitors. Trained project staff will call participants to provide companionship, emotional support, and a friendly conversation. In addition, the callers will conduct a biweekly assessment of depressive symptoms using the patient health questionnaire (PHQ-9), to mirror the biweekly in-app PHQ-9 assessments with the experimental group.

Primary Outcomes

  • Change in Patient Health Questionnaire-9 (PHQ-9) (Change from Baseline to follow-up assessments at 12, 24, and 36 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-01
Completion: 2029-07
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: false
Enrollment: 256 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Michigan
Collaborators: National Institute of Mental Health (NIMH), NYU Silver School of Social Work
Principal Investigators:
  • Xiaoling Xiang, PhD (PRINCIPAL_INVESTIGATOR) - University of Michigan
Contact Information
Study Contact:
Xiaoling Xiang, PhD
734-763-6581
xiangxi@umich.edu
Xiaoling Xiang, PhD
xiangxi@umich.edu
University of Michigan
Xiaoling Xiang, PhD
University of Michigan
Interventions
  • Behavioral: Empower@Home: An online cognitive-behavioral therapy self-care program for geriatric depression — Empower@Home is an online self-help intervention based on cognitive behavioral therapy principles designed to treat depressive symptoms in older adults. The intervention has three components: 9 interactive self-paced online sessions, printed workbook that goes along the online sessions for exercises and homework, and telephone coaching by a trained staff from a social service agency serving older adults. The online sessions contain entertainment elements in the form of a character-driven story of a homebound older adults, video-based psycho-educational content, voice-over instructions, interactive exercises, and weekly home practice assignments.
  • Other: Telephone friendly visits — Participants in the waitlist control group will receive attention control through biweekly telephone-friendly visitors. Trained project staff will call participants to provide companionship, emotional support, and a friendly conversation. In addition, the callers will conduct a biweekly assessment of depressive symptoms using the patient health questionnaire (PHQ-9), to mirror the biweekly in-app PHQ-9 assessments with the experimental group.
Study Locations (1 sites)
University of Michigan, Ann Arbor, Michigan 48109 United States
Eligibility Criteria
Inclusion Criteria: * (1) be receiving or eligible to receive services at the recruitment sites * (2) read and speak English * (3) be at least 50 years old * (4) have at least moderate depressive symptoms at screening (≥ 8 on the Patient Health Questionnaire-9 \[PHQ-9\]). * (5) Participants who are NOT currently receiving outside therapy must agree NOT to start outside therapy during study participation. Participants who are currently receiving outside therapy must agree NOT to increase their outside therapy frequency during study participation. Exclusion Criteria: * (1) probable dementia based on the Blessed Orientation and Memory Scale. * (2) moderate or high risk of suicide based on the 6-item Columbia-Suicide Severity Rating Scale * (3) a terminal illness with less than six months to live or unstable physical health conditions based on self-report * (4) a diagnosis of a psychotic disorder like schizophrenia or bipolar disorder based on self-report and medical chart review * (5) severe vision impairment based on self-report (i.e., legally blind) * (6) current substance use disorders or receiving substance use treatment. * (7) currently receiving outside therapy more frequently than once a month or have started a new therapy treatment less than 3 months ago
Conditions Postpartum Depression (PPD)
Phase PHASE4
Enrollment 2860
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

The objectif of the IRON-DEP Study is to assess the efficacy of intravenous (IV) versus oral iron treatment on the prevalence of postpartum depression (PPD) in women with moderate iron deficiency anemia after caesarean delivery.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Drug: Ferric carboxymaltose IV — Single dose of Ferric carboxymaltose 1000 mg (20mL) IV infusion (20ml vial of 1000mg iron or two 10ml vials of 500mg)
  • Drug: TIMOFÉROL® — 100 mg once a day (2 pills of TIMOFÉROL® 50mg)

Primary Outcomes

  • Prevalence of PostPartum Depression (PPD) symptoms defined by an Edinburg Postpartum Depression Scale (EPDS) score ≥ 11 (8 weeks postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-10-22
Completion: 2028-10-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 2860 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Principal Investigators:
  • Marie-Pierre BONNET, MD, PhD (PRINCIPAL_INVESTIGATOR) - Assistance Publique - Hôpitaux de Paris
  • Catherine DENEUX-THARAUX, MD, PhD (STUDY_DIRECTOR) - Assistance Publique - Hôpitaux de Paris
Contact Information
Study Contact:
Marie-Pierre BONNET, MD, PhD
(+) 33 1 71 73 89 56
marie-pierre.bonnet@aphp.fr
Sarra POCHON, MD
0033 1 42 16 75 74
sarra.pochon@aphp.fr
Interventions
  • Drug: Ferric carboxymaltose IV — Single dose of Ferric carboxymaltose 1000 mg (20mL) IV infusion (20ml vial of 1000mg iron or two 10ml vials of 500mg)
  • Drug: TIMOFÉROL® — 100 mg once a day (2 pills of TIMOFÉROL® 50mg)
Study Locations (1 sites)
CHU Armand -Trousseau, AP-HP Service d'anesthésie-réanimation chirurgicale, Paris, 75012 France
Eligibility Criteria
Pre-inclusion criteria: * Age ≥18 years * Caesarean delivery (elective or in emergency) * Gestational age at delivery ≥ 32 weeks * 8.0 g/dL ≤ postoperative Hb level ≤ 10.0 g/dL measured within 72 hours postpartum * Informed consent form signed * Hospitalization in the postpartum maternity ward * National social security coverage including AME Inclusion criteria: * Ferritinemia ≤ 100 ng/mL OR transferrin saturation ≤ 20% measured after postoperative Hb level measurement * EPDS score in the immediate postpartum \<13 with a "never" answer to question n°10 Exclusion Criteria: * Stillbirth or neonatal death * Last body weight available before inclusion (measured at the end of pregnancy or in postpartum) \< 35kg or \> 100kg * Biermer disease * Hemochromatosis * Homozygous sickle cell disease or thalassemia * Chronic iron supplementation (outside pregnancy) * Known hypersensitivity or allergy to the studied drugs (IV or oral iron) * Contra-indication to the studied drugs (IV or oral iron) * Severe asthma (with daily background treatment) * Any known severe renal or liver disorder * Active acute infection * Diagnosis of schizophrenia or physical and intellectual state incompatible with a reliable self-evaluation * Women currently treated with medication or with Electro Convulsion Therapy (ECT) for depression or bipolar disorders * Participation in another clinical trial involving an intervention with the following risks: * A change (increase or decrease in value) in Haemoglobin measured at 2 months postpartum OR * A change in EPDS score measured at 2 and 6 months postpartum OR * A trial exploring an intervention with a specific anaphylactic risk (reported as a potential adverse events in the protocol of the other trial) administered during the postpartum hospitalization period. * Poor understanding of the French language * Legal protection (curatorship or tutorship)
Conditions Severe Mental Illness, Schizophrenia, Bi...
Phase NA
Enrollment 20
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates a group-based intervention designed to improve romantic and social relationship skills in adults living with a severe mental illness (SMI), such as schizophrenia, bipolar disorder, or major depressive disorder. Many adults with SMI experience loneliness, social isolation, and difficulties forming romantic relationships, even though most express a strong desire for intimacy. These challenges may be related to social skill difficulties, stigma, low self-esteem, and limited opportunities to develop healthy relationships. The "À deux, c'est mieux" (Better Together) program is a structured 12-session group intervention focused on developing communication skills, emotional regulation, social understanding, and healthy romantic relationship behaviors. Sessions are led by trained mental health professionals and take place in small groups. Participants will complete assessments before starting the program, at the end of the 12 sessions, and three months later. The study will examine changes in romantic relationship skills, quality of life, loneliness, self-esteem, self-stigma, and recovery. The purpose of this study is to determine whether this intervention improves romantic and social functioning and overall well-being, and whether it is acceptable and relevant for adults living with severe mental illness.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: À deux, c'est mieux (Better Together) Group Intervention — The "À deux, c'est mieux" intervention is a manualized, group-based psychosocial program consisting of 12 weekly sessions. The program targets the development of romantic relationship skills, including communication, emotional regulation, social cognition, and intimacy-related behaviors. Sessions follow a progressive structure, beginning with relationship initiation and communication skills and gradually addressing more sensitive topics such as emotional intimacy, attachment-related anxiety, and sexuality. The intervention is inclusive of sexual and gender diversity and is delivered by trained mental health professionals in groups of 4 to 6 participants.

Primary Outcomes

  • Change in Romantic Relationship Functioning (Baseline (pre-intervention), end of the 12-session intervention, and 3-month follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-03
Completion: 2026-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre hospitalier de Ville-Evrard, France
Principal Investigators:
  • Raluca ROSETTI, Principal Investigator (PRINCIPAL_INVESTIGATOR) - Psychiatrist, EPS Ville-Evrard
Contact Information
Study Contact:
Youcef BENCHERIF, Clinical Project Manager
00.33.01.43.09.32.32
y.bencherif@epsve.fr
Sabrina HAMMAR, Nurse
00.33.1.55.83.01.80
s.hammar@epsve.fr
HDJ (Hôpital de Jour)
Bachra BARBOUCHA, Nurse
00.33.1.55.83.01.80
b.barboucha@epsve.fr
HDJ (Hôpital de Jour)
Interventions
  • Behavioral: À deux, c'est mieux (Better Together) Group Intervention — The "À deux, c'est mieux" intervention is a manualized, group-based psychosocial program consisting of 12 weekly sessions. The program targets the development of romantic relationship skills, including communication, emotional regulation, social cognition, and intimacy-related behaviors. Sessions follow a progressive structure, beginning with relationship initiation and communication skills and gradually addressing more sensitive topics such as emotional intimacy, attachment-related anxiety, and sexuality. The intervention is inclusive of sexual and gender diversity and is delivered by trained mental health professionals in groups of 4 to 6 participants.
Study Locations (2 sites)
HDJ (Hôpital de Jour), Épinay-sur-Seine, Île-de-France Region 93800 France
L'UNIRRE (Unité Référente de Réhabilitation), Neuilly-sur-Marne, Île-de-France Region 93330 France
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years and older * Diagnosis of a severe mental illness (e.g., schizophrenia, bipolar disorder, or major depressive disorder) * Currently single * Motivated to improve romantic and social relationships and to pursue a romantic relationship * Received mental health care within the past two years * Able and willing to provide informed consent Exclusion Criteria: * Inability to speak or read French * Currently receiving acute or crisis-level psychiatric care * Unable to comply with study procedures or group rules (e.g., maintaining sobriety during sessions)
Conditions Major Depressive Disorder, Chronic Major...
Phase PHASE4
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Sertraline — 50-200mg/day

Primary Outcomes

  • Change from Baseline on the GRID Hamilton Depression Rating Scale (GRID-HAM-D) at 8 weeks (8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2023-09-30
Completion: 2027-07-15
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Texas at Austin
Collaborators: Lehigh University
Contact Information
Study Contact:
Greg Fonzo, Ph.D.
512-495-5856
fonzolab@austin.utexas.edu
Lauren Enten, B.S.A
lauren.enten@austin.utexas.edu
Lauren Enten, B.S.A.
512-495-5856
lauren.enten@austin.utexas.edu
Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600
Interventions
  • Drug: Sertraline — 50-200mg/day
Study Locations (1 sites)
Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, Austin, Texas 78712 United States
Eligibility Criteria
Inclusion Criteria: * English as primary language, and comprehension suitable to understand experimenter instructions * Meet criteria for a current major depressive episode diagnosed through the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) (SCID-5) * Meet criteria for early onset (prior to age 30) of depression and either: a) current major depressive episode lasts for \> 2 years; or b) participant meets criteria for recurrent major depression as evidenced by 2 or more major depressive episodes (including current episode) in their lifetime. These criteria will be assessed by the SCID-5. * Have a Quick Inventory of Depression Symptomology Self-Report Measures (QIDS) score \> 14 at baseline and the week prior to first Sertraline administration * Willing and able to undergo MRI and EEG procedures. Exclusion Criteria: * Non-early onset (i.e., after age 30), non-chronic (current episode lasting less than 2 years or only one lifetime major depressive episode, including current episode) qualifying Major Depressive Disorder * Must not have failed to respond to any prior antidepressant treatment in the current episode of sufficient duration and dose as defined by the Massachusetts General Hospital (MGH) Antidepressant Treatment Response Questionnaire * Currently pregnant, planning to become pregnant, or breastfeeding * Evidence of current or prior history of psychosis or bipolar disorder as evidenced by self-report or clinical interview * Meeting DSM-5 criteria for a substance-use disorder of moderate or greater severity in the past 6 months * Unstable psychiatric or medical conditions that may require hospitalizations or contraindicate study medication (i.e. autism spectrum disorder, schizophrenia, cancer, congestive heart failure, etc.) * Contraindications to MRI including, but not limited to, history of stroke, brain tumors, brain hemorrhages, internal wires, electrodes, pacemakers, implants, irremovable ferromagnetic objects in head that are unsafe for MRI and/or cause large distortions in imaging data, etc. * History of epilepsy, moderate or severe traumatic brain injury, penetrating head injury, brain surgery, brain tumors, or any condition requiring an anticonvulsant * Treatment with electroconvulsive therapy, vagus nerve stimulation, or transcranial magnetic stimulation during the current depressive episode * Concomitant medication use that are likely to interfere or obscure effects from the study medication, including but not limited to antipsychotics and mood stabilizers * Current regular depression-specific evidence-based psychotherapy treatment * Considered by the investigative team to be a significant suicide risk as evidence by self-report or clinical interview
Conditions Depression, Anxiety
Phase NA
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

Research shows that the single lesson 'Things You Do' Intervention is effective in increasing engagement in everyday healthy actions. However, no research has examined whether its effectiveness is enhanced by incorporating personalized feedback on participants' current level of engagement in healthy actions. In this randomized controlled trial, clients will be randomly assigned to either receive or not receive personalized feedback informing them of their level of engagement in healthy actions over the previous week and encouraging them to participate in more healthy activities. The investigators will examine whether this feedback increases engagement in healthy actions and enhances the effectiveness of the 'Things You Do' Intervention as assessed through changes in primary outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Things You Do Program (Ultra-Brief ICBT) — The TYD program is an ultra-brief ICBT intervention developed at Macquarie University, Australia. The intervention provides psychoeducation on mental health and five areas of healthy actions, known as the "Things You Do," along with practical skills to support engagement in these actions. These five areas include Meaningful Activities, Healthy Thinking, Goals and Plans, Healthy Habits, and Social Connections. The intervention includes a single lesson, a Weekly Planner, an Activity Guide, and a daily 'Tip of the Day' Offered for 30 days. The lesson content is presented across 25 slides using text and infographics and requires approximately 30-60 minutes to review. A key component of the TYD intervention is the daily 'Tip of the Day.' These are daily messages that clients receive for 30 days following the start of the intervention. Each message provides a tip or suggests a healthy action that clients can engage in that day. Clients complete the program without therapist support.
  • Behavioral: Things You Do Program Plus Personalized Feedback — Participants in this arm receive the same Things You Do (TYD) intervention as those in the comparative arm, with the addition of personalized feedback report. The TYD program is an ultra-brief ICBT intervention providing psychoeducation on mental health and five areas of healthy actions: Meaningful Activities, Healthy Thinking, Goals and Plans, Healthy Habits, and Social Connections. The intervention includes a single lesson (25 slides), Weekly Planner, Activity Guide, and daily "Tip of the Day" delivered for 30 days following enrollment in the intervention. Participants complete the intervention independently without therapist support. In addition to the standard TYD intervention, participants in this arm receive a personalized feedback report at screening, in Week 3, and in Week 5 following enrollment. Reports provide individualized feedback on participants' engagement across the five areas of healthy actions and are intended to encourage and motivate engagement in these areas.

Primary Outcomes

  • Things You Do-15 (TYD-15) (Baseline (intake), week 3 and 5)
  • Patient Health Questionnaire-9 (PHQ-9) (Baseline (intake), weeks 3 and 5)
  • Generalized Anxiety Disorder - 7 (GAD-7) (Baseline (intake), weeks 3 and 5)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-11
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Regina
Collaborators: Macquarie University, Australia
Principal Investigators:
  • Heather Hadjistavropoulos, PhD (PRINCIPAL_INVESTIGATOR) - University of Regina
Contact Information
Study Contact:
Marcie Nugent
306-337-3331
marcie.nugent@uregina.ca
Heather Hadjistavropoulos
306-585-5133
heather.hadjistavropoulos@uregina.ca
Marcie Nugent
306-337-3331
marcie.nugent@uregina.ca
Online Therapy Unit
Interventions
  • Behavioral: Things You Do Program (Ultra-Brief ICBT) — The TYD program is an ultra-brief ICBT intervention developed at Macquarie University, Australia. The intervention provides psychoeducation on mental health and five areas of healthy actions, known as the "Things You Do," along with practical skills to support engagement in these actions. These five areas include Meaningful Activities, Healthy Thinking, Goals and Plans, Healthy Habits, and Social Connections. The intervention includes a single lesson, a Weekly Planner, an Activity Guide, and a daily 'Tip of the Day' Offered for 30 days. The lesson content is presented across 25 slides using text and infographics and requires approximately 30-60 minutes to review. A key component of the TYD intervention is the daily 'Tip of the Day.' These are daily messages that clients receive for 30 days following the start of the intervention. Each message provides a tip or suggests a healthy action that clients can engage in that day. Clients complete the program without therapist support.
  • Behavioral: Things You Do Program Plus Personalized Feedback — Participants in this arm receive the same Things You Do (TYD) intervention as those in the comparative arm, with the addition of personalized feedback report. The TYD program is an ultra-brief ICBT intervention providing psychoeducation on mental health and five areas of healthy actions: Meaningful Activities, Healthy Thinking, Goals and Plans, Healthy Habits, and Social Connections. The intervention includes a single lesson (25 slides), Weekly Planner, Activity Guide, and daily "Tip of the Day" delivered for 30 days following enrollment in the intervention. Participants complete the intervention independently without therapist support. In addition to the standard TYD intervention, participants in this arm receive a personalized feedback report at screening, in Week 3, and in Week 5 following enrollment. Reports provide individualized feedback on participants' engagement across the five areas of healthy actions and are intended to encourage and motivate engagement in these areas.
Study Locations (1 sites)
Online Therapy Unit, Regina, Saskatchewan S4S0A2 Canada
Eligibility Criteria
Inclusion Criteria: * Canadian resident; * Aged 18 years or older; * Access to a computer (or another appropriate device) and the Internet; * Willingness to learn information and skills to self-manage mental health difficulties. Exclusion Criteria: * Unable to read and understand English (All content is provided in English ).
Conditions Psychological Stress, Depression, Anxiet...
Phase PHASE2
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders. The study will also investigate the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Psilocybin — Psilocybin 25mg, capsules taken orally under the supervision of two trained study therapists
  • Behavioral: Integration sessions — weekly integration sessions (therapy) for 6 weeks

Primary Outcomes

  • Columbia-Suicide Severity Rating Scale (C-SSRS) (up to 23 weeks)
  • Brief Psychiatric Rating Scale (BPRS-6) (up to 23 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-08-28
Completion: 2030-01-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rachel Yehuda
Principal Investigators:
  • Rachel Yehuda, PhD (PRINCIPAL_INVESTIGATOR) - Icahn School of Medicine at Mount Sinai
Contact Information
Study Contact:
Lauren Lepow, MD, PhD
646-438-5044
lauren.lepow@mountsinai.org
Evelyn Alkin, MA
929-489-7440
IntergenStudy@mssm.edu
Interventions
  • Drug: Psilocybin — Psilocybin 25mg, capsules taken orally under the supervision of two trained study therapists
  • Behavioral: Integration sessions — weekly integration sessions (therapy) for 6 weeks
Study Locations (1 sites)
The Parsons Research Center for Psychedelic Healing, New York, New York 10025 United States
Eligibility Criteria
Inclusion Criteria: * Age at least 18 years old at time of signing the informed consent. * Biological child of at least one parent who directly survived/escaped a genocide. * Evidence of clinically significant intergenerational trauma-related symptoms, as determined by the modified Parental PTSD Questionnaire (mPPQ). * Meet diagnostic criteria for a depressive, anxiety, trauma-, or stressor-related disorder on the Structured Clinical Interview for DSM-5 (SCID-5). * BMI of ≥ 17. * Capable of providing written informed consent and complying with study procedures. * If of reproductive potential, willing to use a highly effective method of contraception throughout study participation. Participants who can father a child and have partners of reproductive potential must also agree to use effective contraception throughout study participation. * Willing and medically appropriate to discontinue serotonergic medications before study treatment and remain off such medications throughout study participation, as determined by the study physician in consultation with the participant's treating healthcare provider. * Fluent in speaking and reading English. * Able to swallow pills. * Agree to have all study visits (both in-person and remote) recorded with audio and video. * Able to provide a contact person who can be reached by investigators in the event of the participant becoming unwell or unreachable. * Must agree to inform the investigators within 48 hours of any medical conditions and procedures. * Agree to release relevant medical and psychiatric records for eligibility determination and safety monitoring. * Agree to comply with protocol-specified lifestyle restrictions and study requirements. Safety note (not incl./excl. criteria): Note to Potential Participants: Individuals interested in this study should not stop, taper, or otherwise change prescribed medications before speaking with the study team. Any medication changes required for study participation will be evaluated by qualified study clinicians and, when appropriate, coordinated with the participant's treating healthcare provider. Exclusion Criteria: * Individual was directly exposed to the genocide. * Current or recent illicit drug or prescription drug substance use disorder (excluding cannabis and tobacco use disorders), as determined by DSM-5 criteria and clinical assessment. * Current or recent alcohol or cannabis use disorder that, in the opinion of the investigator, may interfere with safe participation or study outcomes. * Current psychiatric hospitalization or psychiatric hospitalization within the last 6 months. * Recent use of psychedelic substances. * Recent non-medical or illicit use of ketamine. * Past or current psychotic disorder (including psychotic MDD), mania, or bipolar disorder. * Current serious suicide risk, recent suicidal behavior, or clinician concern that the participant poses a risk to self or others. * Acute, severe, or unstable medical illness, including clinical or laboratory evidence of severe renal and/or hepatic impairment. * Any physical or intellectual disability adversely affecting ability to complete assessments. * Current pregnancy or currently chest/breastfeeding. * Any clinically meaningful abnormal laboratory test result, as determined by the investigator. * Current treatment with medications contraindicated with study treatment that cannot be safely tapered, discontinued, or substituted in accordance with the protocol. * History of clinically significant QT prolongation or other clinically significant cardiac conduction abnormality. * Use of medications known to prolong the QT interval that cannot be safely discontinued. * Any congenital prolongation of the QT interval or a family history of long QT syndrome. * A family history in a first-degree relative of psychosis/schizophrenia or related disorders as assessed by clinical interview with Study MD. * A first-degree family history of bipolar disorder as assessed by clinical interview with Study MD. * Current anorexia nervosa or bulimia nervosa as determined by DSM-V criteria using the SCID-V. * A clinically meaningful history of cardiac arrhythmias or who require treatment with an antiarrhythmic medication. * Preexisting clinically meaningful cardiovascular conditions, including cardiac valvulopathy, pulmonary hypertension that may be worsened/exacerbated by elevated blood pressure or heart rate. * Neurological conditions including stroke, transient ischemic attack (TIA), epilepsy, neurodegenerative disease, brain tumor, or other neurological disorders that would impact participation in the trial. * Insulin-dependent diabetes. * Vital sign abnormalities at screening that exceed protocol-defined safety thresholds. * Hypersensitivity to psilocybin. * Psychiatric or other condition judged to be incompatible with establishment of rapport with therapy team and/or safe exposure to psilocybin. * Positive toxicology findings not adequately explained by prescribed medications or approved treatment regimens. * Clinically meaningful abnormalities on screening electrocardiogram (ECG). * Fall risk if not mitigated by assistance from study staff. * Can't identify a support person who will be able to accompany them home and stay the night with them post experimental session.
Conditions Depression
Phase PHASE1
Enrollment 64
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

Background: Researchers developed \[11C\]MC1, a radioligand for cyclooxygenase-2 (COX-2). COX-2 is an enzyme induced in the brain during inflammation. Researchers want to see the levels of COX-1 (measured as distribution volume VT) are elevated in the brain of two groups of mood disorders patients undergoing MDE relative to the control group. Objective: To determine whether COX-1 and COX-2 are detectable in the brains of individuals with MDD experiencing a major depressive episode (MDE). Eligibility: People aged 18-70 years with MDD and Healthy Volunteers aged 18 70 years. Design: Group A: MDD participants will be studied with the same dose of \[11C\]MC1 before and after administration of 600 mg celecoxib; the study is neither randomized nor placebo-controlled. Group B: MDD participants, both medicated and unmedicated, will be studied with \[11C\]PS13 and compared to healthy volunteers.. https://nimhcontent.nimh.nih.gov/start/surveys/?s=TJW4RA4WN3LDD988

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: 11C-MCI — Injected IV followed by PET scanning
  • Drug: 11CPS13 — Injected IV followed by PET scanning

Primary Outcomes

  • Measure the concentration of radioligands (36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2021-07-20
Completion: 2030-04-11
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: true
Enrollment: 64 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Robert B Innis, M.D. (PRINCIPAL_INVESTIGATOR) - National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Tara N Turon, C.R.N.P.
(301) 827-6599
tara.turon@nih.gov
Robert B Innis, M.D.
(301) 594-1368
robert.innis@nih.gov
For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
800-411-1222
prpl@cc.nih.gov
National Institutes of Health Clinical Center
Interventions
  • Drug: 11C-MCI — Injected IV followed by PET scanning
  • Drug: 11CPS13 — Injected IV followed by PET scanning
Study Locations (1 sites)
National Institutes of Health Clinical Center, Bethesda, Maryland 20892 United States
Eligibility Criteria
* INCLUSION CRITERIA: Patients: In order to be eligible for this study, MDD participants must meet all of the following criteria: 1. Aged 18 to 70 years old. 2. Female participants of childbearing potential must be using a medically acceptable means of contraception. 3. Participants must be in good general health as evidenced by medical history and physical examination. 4. Each participant must have a level of understanding sufficient to agree to all required tests and examinations and sign an informed consent document. 5. All participants must have undergone a screening assessment under protocol 01M0254, The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Participants . 6. Participants must fulfill DSM-5 criteria for major depression (MDD) without psychotic features, as based on clinical assessment and structured diagnostic interview (SCID-P). 7. Participants must have an initial score on the MADRS greater than or equal to 18 or HAM-D greater than or equal to 15 within one week of study entry. 8. Participants must be experiencing an MDE lasting at least four weeks. 9. Unmedicated participants in both Groups must be medication-free for at least two weeks (5 weeks for aripirazole, brexpiprazole, fluoxetine) prior to first screen visit. Medications will not be discontinued for the purpose of this study. 10. Participants must have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists. 11. Participants must agree to adhere to the lifestyle considerations. Healthy Controls: In order to be eligible to participate in this study, control subjects must meet all of the following criteria: 1. Aged 18 to 70 years old. 2. Female participants of childbearing potential must be using a medically acceptable means of contraception. 3. Able to provide informed consent. 4. Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment. 5. Be enrolled in 01M0254, The Evaluation of Participants with Mood and Anxiety Disorders and Healthy Volunteers or 17M0181, Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies . 6. Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists. 7. Agree to adhere to the lifestyle considerations. EXCLUSION CRITERIA: Participants with MDD who meet any of the following criteria will be excluded from participation in this study: 1. Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). Any lab value that is two-times the upper limit or even lower values in the investigator s judgment. Creatinine level \>1.3 mg/dL. 2. Participants must be free of all prohibited medications or at least two weeks (5 weeks for aripiprazole, brexpiprazole, fluoxetine) prior to screen visit. These medications include antidepressants, anti-inflammatory drugs (except for study medication celecoxib), antipsychotics, anxiolytics, psychotropic drugs not otherwise specified (including herbal products), and sedatives/hypnotics. Medicated participants in Group B may continue their therapy. 3. Participants should not have taken Non-Steroidal Anti-Inflammatory Drug (NSAID)s for two weeks prior to the PET scan. Aspirin, corticosteroids (with the exception of topical steroids), or immunosuppressants (e.g. methotrexate) must not have been taken in the prior month. 4. Current psychotic features or a diagnosis of schizophrenia or any other psychotic disorder as defined in the DSM-5. 5. Participants with a history of DSM-5 substance use disorder (except for caffeinei or nicotine dependence) within the preceding three months. In addition, participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs function of daily lfe. 6. Participants who, in the investigator s judgment, pose a current serious suicidal or homicidal risk. 7. Participants who have a history of aggressive behavior towards others. 8. Participants who have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy). 9. Participants seeking treatment or a change in treatment and may be referred to the community or to another research study. 10. Are unable to travel to the NIH. 11. Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits. 12. Have an inability to lie flat and/or lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the participant during the screening visit. 13. Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye. 14. Pregnancy. 15. HIV Infection. 16. Be NIMH staff or an NIH employee who is a subordinate/relative/co-worker of the investigators. Healthy controls who meet any of the following criteria will be excluded from participation in this study: 1. Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). 2. Participants must be free of all prohibited medications or at least two weeks (5 weeks for aripiprazole, brexpiprazole, fluoxetine) prior to screen visit. These medications include antidepressants, anti-inflammatory drugs (except for study medication celecoxib), antipsychotics, anxiolytics, psychotropic drugs not otherwise specified (including herbal products), and sedatives/hypnotics. 3. Participants should not have taken NSAIDs for two weeks prior to the PET scan. Aspirin, corticosteroids, or immunosuppressants (e.g. methotrexate) must not have been taken in the prior month. 4. Participants with a history of DSM-5 substance use disorder (except for caffeine or nicotine dependence) within the preceding three months. In addition, participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs function of daily life. 5. Participants who have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy). 6. Are unable to travel to the NIH. 7. Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits. 8. Have an inability to lie flat and/or lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the participant during the screening visit. 9. Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye. 10. Pregnancy. 11. HIV Infection. 12. Be NIMH staff or an NIH employee who is a subordinate/relative/co-worker of the investigators. EXCLUSION O
Conditions Postpartum Depression (PPD), Labor Analg...
Phase Not Applicable
Enrollment 3640
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

Postpartum Depression (PPD) is defined as the development of depression at any time during the first year after childbirth¹. Its prevalence ranges from 15% to 20%. It can manifest with symptoms such as depressed mood, loss of interest and energy, insomnia, anxiety, and may even lead to suicidal ideation. The consequences are numerous, both physical and psychological, with long-term repercussions on the mother-infant bond, family dysfunction, and the development of emotional and cognitive disorders in children. The etiology of PPD is multifactorial, but numerous recent studies have focused on the role of labor pain and its management with labor analgesia techniques. The aim of the present study is therefore to assess whether there is a difference in the incidence of PPD between parturients whose expectations regarding labor analgesia were met ('expectations met' group) versus those whose expectations were unmet.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Epidural analgesia — Analgesia via epidural catheter using local anesthetic ± opioid, administered on patient request during labor.
  • Procedure: Spinal analgesia for labour pain — Single-shot spinal analgesia
  • Other: No neuraxial analgesia — Patients did not received spinal or epidural labour analgesia

Primary Outcomes

  • incidence of postpartum depression (6 months since labour)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-08
Completion: 2029-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 3640 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Padova
Contact Information
Study Contact:
Fabrizia Calabrese, MD
+39 0498213090
fabrizia.calabrese@aopd.veneto.it
Giulia Faccioli, MD
giuliafdg@gmail.com
Alessandro De Cassai, MD
University Hospital of Padova
Interventions
  • Procedure: Epidural analgesia — Analgesia via epidural catheter using local anesthetic ± opioid, administered on patient request during labor.
  • Procedure: Spinal analgesia for labour pain — Single-shot spinal analgesia
  • Other: No neuraxial analgesia — Patients did not received spinal or epidural labour analgesia
Study Locations (1 sites)
University Hospital of Padova, Padova, Veneto 35127 Italy
Eligibility Criteria
Inclusion Criteria: * Signed informed consent * Planned vaginal delivery (spontaneous or induced) * Pregnancy * Age \> 18 years Exclusion Criteria: * Allergy to local anesthetics * Language barrier * Contraindications to labor analgesia * Delivery by Cesarean section * Known history of psychiatric disorders (including major depression)
Conditions Schizophrenia, Bipolar Disorder, Depress...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

Many individuals with serious mental illness have difficulty accurately interpreting interpersonal cues and effectively engaging in social exchanges. Difficulties related to the interpersonal aspects of work can lead to isolation, poor productivity, and job loss. The goals of this study are to: 1) adapt an evidence-based social cognitive skills intervention for work settings and use with Veterans, 2) examine the acceptability of the work focused skills training intervention, 3) assess the feasibility of combining the social cognitive skills training program with supported employment, and 4) examine change on functional outcomes. The current study will use feedback from veteran and employment specialist stakeholders to adapt an evidence-based social cognitive skills training program, Social Cognition and Interaction Training (SCIT). The intervention will be modified to tailor it to work relationships and to address any unique relationship concerns among Veterans that are identified by stakeholders. SCIT-Work Edition (SCIT-WE) will add: 1) education about work-related social norms; 2) examples of work-related social interactions that require perspective taking and problem- solving; 3) individual sessions with the study therapist to enhance learning and relevance to each participant's goals; 4) structured interactions with the participant's employment specialist to practice skills outside of group; and 5) skill application sessions with the participant's employment specialist that prompt use of skills after training is completed. SCIT-WE will be developed and piloted in an open trial with 20 Veterans enrolled in the supported employment program at the Minneapolis VA who have a qualifying serious mental illness diagnosis. SCIT-WE will be offered for 2 hours weekly over 13 weeks, when most participants are in the job development and job search phases of supported employment. While participating in the group skills training, participants will have weekly, individual homework review sessions with the group facilitator to promote understanding of the skills and to discuss relevance of the skills to personal goals. Participants also will practice skills weekly with their employment specialist for 10-15 minutes to promote use of skills outside of group sessions. In the 3-months following skills training completion, participants will complete 10 15-minute skills review sessions with their employment specialist to encourage continued skill application in a work setting. Participants will complete assessments at baseline, before receiving the intervention; 3-months post-enrollment, after participating in a weekly skills training group; and 6-months post-enrollment, after receiving 10 additional individual skills review sessions with their employment specialist. Accessibility will be measured with rate of treatment uptake, rate of treatment completion, and participant attitudes toward the intervention. Feasibility of the intervention will be assessed by…

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Social Cognition and Interaction Training-Work Edition (SCIT-WE) — Participants will attend 1 2-hour skills training group weekly for 13 weeks after enrolling in supported employment. In addition to the group session, participants have a 15-30 minute individual session with the group facilitator weekly to review homework and complete a 10-15 minute exercise with their employment specialist each week to practice skills outside of group. The 13-week skills group is followed by 10 skills review/application sessions conducted during 10 supported employment sessions in the next 13 weeks.

Primary Outcomes

  • Social Adjustment Scale-Self-Report: Short Version (SAS-SR: Short) Change (Baseline and 3 months)
  • Social Adjustment Scale-Self-Report: Short Version (SAS-SR: Short) Change (Baseline and 6 months)
  • Recovering Quality of Life (ReQoL)-20 Change (Baseline and 3 months)
  • Recovering Quality of Life (ReQoL)-20 Change (Baseline and 6 months)
  • Return to Work Self-Efficacy Scale (RTW-SE) Change (Baseline and 3 months)
  • Intrinsic Motivation Inventory - Interest subscale (3 months)
  • Intrinsic Motivation Inventory - Interest subscale (6 months)
  • Intrinsic Motivation Inventory - Value subscale (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-12-01
Completion: 2028-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VA Office of Research and Development
Principal Investigators:
  • Tasha Marie Nienow, PhD (PRINCIPAL_INVESTIGATOR) - Minneapolis VA Health Care System, Minneapolis, MN
Contact Information
Study Contact:
Tasha M Nienow, PhD
(612) 467-1004
Tasha.Nienow@va.gov
Laura A Meis, PhD
(612) 467-4516
laura.meis@va.gov
Tasha M Nienow, PhD
(612) 467-1004
Tasha.Nienow@va.gov
Minneapolis VA Health Care System, Minneapolis, MN
Interventions
  • Behavioral: Social Cognition and Interaction Training-Work Edition (SCIT-WE) — Participants will attend 1 2-hour skills training group weekly for 13 weeks after enrolling in supported employment. In addition to the group session, participants have a 15-30 minute individual session with the group facilitator weekly to review homework and complete a 10-15 minute exercise with their employment specialist each week to practice skills outside of group. The 13-week skills group is followed by 10 skills review/application sessions conducted during 10 supported employment sessions in the next 13 weeks.
Study Locations (1 sites)
Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota 55417-2309 United States
Eligibility Criteria
Inclusion Criteria: * Veterans who are outpatients and enrolled to receive supported services at the Minneapolis VA Health Care System * Veterans are eligible for this program if they are receiving services from a mental health team at the Minneapolis VA Health Care System, are motivated to pursue employment, and are seeking employment within 30 miles of the medical center * Veterans will be eligible for the study if they have a DSM-5 diagnosis of Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Bipolar II Disorder, Recurrent Major Depressive Disorder, or post-traumatic stress disorder (PTSD) Exclusion Criteria: Study exclusion criteria are: * presence of a moderate or severe traumatic brain injury * presence of a cognitively compromising neurological disease * understanding of English that is not sufficient for comprehension of testing procedures * premorbid IQ less than 70 * behavior that prevents participation in a group intervention * hearing or visual impairment that prevents completion of intervention and testing procedures * clinical instability, defined as active suicidal ideation or hospitalization in the previous 4 weeks * current diagnosis of alcohol or substance use disorder, severe * current participation in another mental health intervention study * inability to commit to 7-9 months of study participation due to a planned move or unstable housing * inability to provide informed consent * presence of a guardian of person
Conditions Primary Angle Closure Glaucoma
Phase NA
Enrollment 82
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn whether phacoemulsification combined with goniosynechialysis (Phaco-GSL) is as effective and safe as trabeculectomy in treating patients with primary angle-closure glaucoma. The main questions it aims to answer are: * Does Phaco-GSL provide similar or better intraocular pressure (IOP) control compared to trabeculectomy? * What are the rates of postoperative complications or adverse events between the two surgical approaches? * How do the two procedures compare in terms of visual acuity recovery and need for glaucoma medications? Researchers will compare Phaco-GSL to trabeculectomy to determine which procedure offers better overall outcomes for patients with angle-closure glaucoma. Participants will: Be randomly assigned to undergo either Phaco-GSL or trabeculectomy Attend scheduled follow-up visits at regular intervals (e.g., 1 week, 1 month, 3 months, 6 months, 12 months) for eye exams and pressure checks

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Procedure: Phacoemulsification with Goniosynechialysis — This procedure involves standard phacoemulsification cataract surgery combined with goniosynechialysis, which mechanically separates peripheral anterior synechiae to open the anterior chamber angle. It aims to both remove the cataractous lens and restore aqueous outflow in patients with primary angle-closure glaucoma.
  • Procedure: Trabeculectomy with 5FU — Trabeculectomy is a glaucoma filtration procedure designed to lower intraocular pressure by creating a new drainage pathway from the anterior chamber to the sub-conjunctival space. It is considered the standard surgical intervention for medically uncontrolled glaucoma.

Primary Outcomes

  • Mean change in intraocular pressure (IOP) from baseline (12 months after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-01
Completion: 2027-09-10
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 82 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Medicine and Pharmacy at Ho Chi Minh City
Contact Information
Study Contact:
Hai Thanh Le, MSc
+61 450390405
haileopto@gmail.com
Phuc Hoang Nguyen, MD
+84 983826797
dr.nguyenhoangphuc@ump.edu.vn
HCMC University of Medicine and Pharmacy
Interventions
  • Procedure: Phacoemulsification with Goniosynechialysis — This procedure involves standard phacoemulsification cataract surgery combined with goniosynechialysis, which mechanically separates peripheral anterior synechiae to open the anterior chamber angle. It aims to both remove the cataractous lens and restore aqueous outflow in patients with primary angle-closure glaucoma.
  • Procedure: Trabeculectomy with 5FU — Trabeculectomy is a glaucoma filtration procedure designed to lower intraocular pressure by creating a new drainage pathway from the anterior chamber to the sub-conjunctival space. It is considered the standard surgical intervention for medically uncontrolled glaucoma.
Study Locations (1 sites)
HCMC University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam
Eligibility Criteria
Inclusion Criteria: * Age ≥ 40 years * Peripheral anterior synechiae (PAS) \>180° * Glaucomatous optic neuropathy with visual field loss * Intraocular pressure (IOP) \> 21 mmHg despite medication * Ability to consent and comply with follow-up * Cataract grade 1 to 3 according to LOCS III * Best corrected visual acuity (BCVA) ≥ 0.3 logMAR (equivalent to 20/40 Snellen or worse) Exclusion Criteria: * Very advanced glaucoma (only light perception vision) * Secondary angle-closure etiologies * Prior ocular surgeries or laser peripheral iridotomy (PI) * Allergy to 5-fluorouracil (5-FU), if used postoperatively * Irreversible corneal disease * Chronic corticosteroid use * Poor follow-up compliance * Cataract grade 4 or 5 (LOCS III) * Phacomorphic, phacolytic, or subluxated cataracts
Conditions Pregnancy-induced Hypertension
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

Collect blood pressure, blood, amniotic fluid, placenta and other samples from normal pregnant women, patients with pregnancy-induced hypertension and those who have experienced miscarriage, and conduct tests on them.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: no Intervention — observation

Primary Outcomes

  • PIH (Early pregnancy:Weeks 1 to 12 (the first to third months of pregnancy) ;mid-pregnancy:Weeks 13 to 27 (the 4th to 6th month of pregnancy) ;post-delivery period:Weeks 28 to 40 (the 7th to 9th months of pregnancy);the day of delivery。)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-01-01
Completion: 2028-12-31
Eligibility
Age: 20 Years – 50 Years
Sex: FEMALE
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital of Wenzhou Medical University
Principal Investigators:
  • Qian Wang (STUDY_CHAIR) - The Second Affiliated Hospital of wenzhou Medical University Longwan Branch
Contact Information
Study Contact:
Qian Wang, PHD
13587638653
wqian84@163.com
Qian Wang, PHD
13587638653
wqian84@163.com
The Second Affiliated Hospital of Wenzhou Medical University
Interventions
  • Other: no Intervention — observation
Study Locations (1 sites)
The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000 China
Eligibility Criteria
Inclusion Criteria: \- Healthy pregnant women, patients with miscarriage, etc. Exclusion Criteria: * Heart disease, infections, etc. in pregnant women Uncooperative patients